Drugs / NNC0385-0434
Trials 7 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT05333107 | Apr → Jul 2022 | — | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT05091073 | Dec 2021 → Apr 2022 | atherosclerotic cardiovascular disease, hyperlipoproteinemia | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT05094934 | Nov 2021 → Jul 2022 | chronic kidney disease | Novo Nordisk A/S | Terminated | No outcome recorded |
| Phase 1 | NCT05129891 | Nov 2021 → Feb 2023 | low density lipoprotein cholesterol, mild elevation of, type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT05003440 | Aug 2021 → Jan 2022 | atherosclerotic cardiovascular disease | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT04058834 | Aug 2019 → Apr 2020 | hyperlipidemia | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04992065 | Aug 2021 → Apr 2022 | atherosclerotic cardiovascular disease | Novo Nordisk A/S | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NNC0385-0434 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05091073 ↗ |
| Known as | NN0385-0434 | “A Research Study Looking at the Effect of Food Intake on How the Medicine NN0385-0434 Behaves in the Body of Healthy Participants” NCT05091073 ↗ |
| Action | Inhibit | “This phase 2 study assessed NNC0385-0434, an oral PCSK9 inhibitor, in individuals receiving oral lipid-lowering therapy.” PMID 38310920 ↗ Feb 2024 |
| Route | Subcutaneous | “one injection s.c. (subcutaneously, under the skin)” NCT04058834 ↗ |